Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

SolarCity appoints a two-person committee to decide whether to sell to Tesla

All of SolarCity’s other board members have recused themselves from voting on the proposal.

Asa Mathat

When Elon Musk’s electric car company offers to buy Elon Musk’s solar power company, you better believe things will get complicated.

The two companies (Musk serves as chairman of both) already work closely together — so closely that five of SolarCity’s board members work at Tesla, are on Tesla’s board or are related to someone who is.

To ensure Tesla’s proposal to acquire all of the remaining SolarCity common stock is fairly evaluated, SolarCity’s board of directors has appointed two people the exclusive right to make the decision for the board: Donald Kendall and Nancy Pfund.

The overlap in executives highlights a deeper issue in the merger. It’s not immediately clear what a tie-up between the two companies would bring, and both companies operate at a loss. A merger might just make things worse. Kendall and Pfund will have to determine if the proposal will materially benefit SolarCity shareholders and not just give Musk a way to consolidate his bets.

Kendall, who is the CEO of investment management firm Kenmont Solutions Capital, is the only person on the SolarCity board without a direct connection to Tesla.

Pfund, on the other hand, is the founder and managing partner of DBL Investors, which invested in Tesla and served on the car company’s board before the company went public.

All but one of the other SolarCity board members — company chairman Musk; CEO and Musk’s cousin Lyndon Rive; CTO and other Musk cousin Peter Rive; CEO of Valor equity partners and Tesla board member Antonio Gracias; and Tesla co-founder and CTO J.B. Straubel — have recused themselves from voting on whether to accept Tesla’s $2.8 billion offer. John Fischer, who is a partner in Tesla and SolarCity investor Draper Fisher Ventures, has not officially recused himself.

In a letter Tesla’s board of directors sent to SolarCity’s CEO, the company offered to buy all of SolarCity’s remaining common stock in exchange for Tesla’s common shares for $26.50 to $28.50 a share.

Read this next: Tesla has just put in an offer to acquire SolarCity


This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh